Cristina Petrangelo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Cristina Petrangelo has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Bertolotti
Division of Medical Oncology, Department of Medical and Surgical Sciences for Children and Adults, University Hospital of Modena, 41125 Modena, Italy
1 shared publication - Andrea Spallanzani
Department of Oncology and Hematology, Division of Oncology, University Hospital of Modena, Modena, Italy
1 shared publication - Annalisa Fontana
Division of Medical Oncology, Department of Medical and Surgical Sciences for Children and Adults, University Hospital of Modena, 41125 Modena, Italy
1 shared publication - Bianca Medici
Department of Oncology and Hematology, Division of Oncology, University Hospital of Modena, 41124 Modena, Italy
1 shared publication - Elisa Pettorelli
Department of Training, Research and Innovation, University Hospital of Modena, 41125 Modena, Italy
1 shared publication - Fabio Gelsomino
Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy
1 shared publication
Latest Publications
- Open Access
Colorectal Cancer in Younger and Elderly Patients: A Real-World Analysis from the Modena Cancer Center
Background: Early-onset colorectal cancer represents a growing global health challenge. Although differences between young and elderly patients are recognized, direct comparison of extreme age groups may further characterize their distinct clinical and therapeutic profiles. Methods : This is a retrospective, single-centre, observational study, comparing young patients (Group A: ≤50 years, n = 153) with elderly patients (Group B: ≥75 years, n = 533) during the period 1990–2025. Results: Group A presented higher rates of stage IV presentation (66.9% vs. 47.1%, p < 0.001), T4 tumors, N2 nodal involvement, distal tumor localization and synchronous metastasis (87.5% vs. 70.6%, p = 0.001), predominantly involving the liver and peritoneum. Younger patients received more intensive adjuvant and metastatic systemic treatment. The mOS was 52.8 months for Group A compared to 26.4 months for Group B (HR 2.29, 95% CI 1.57–3.54, p < 0.001) and DFS was longer in Group A (28.6 vs. 19.1 months; HR 2.26, 95% CI 1.55–3.29, p < 0.001). No statistically significant differences were observed in first- or second-line PFS between the cohorts. Conclusions: Early-onset colorectal cancer exhibits a more adverse clinicopathological profile. Younger patients showed longer overall and disease-free survival in this cohort, although these findings should be interpreted with caution given potential differences in treatment exposure, baseline fitness, comorbidity burden and the substantial temporal heterogeneity of the study period.
Open AccessColorectal Cancer in Younger and Elderly Patients: A Real-World Analysis from the Modena Cancer Center
Background: Early-onset colorectal cancer represents a growing global health challenge. Although differences between young and elderly patients are recognized, direct comparison of extreme age groups may further characterize their distinct clinical and therapeutic profiles. Methods : This is a retrospective, single-centre, observational study, comparing young patients (Group A: ≤50 years, n = 153) with elderly patients (Group B: ≥75 years, n = 533) during the period 1990–2025. Results: Group A presented higher rates of stage IV presentation (66.9% vs. 47.1%, p < 0.001), T4 tumors, N2 nodal involvement, distal tumor localization and synchronous metastasis (87.5% vs. 70.6%, p = 0.001), predominantly involving the liver and peritoneum. Younger patients received more intensive adjuvant and metastatic systemic treatment. The mOS was 52.8 months for Group A compared to 26.4 months for Group B (HR 2.29, 95% CI 1.57–3.54, p < 0.001) and DFS was longer in Group A (28.6 vs. 19.1 months; HR 2.26, 95% CI 1.55–3.29, p < 0.001). No statistically significant differences were observed in first- or second-line PFS between the cohorts. Conclusions: Early-onset colorectal cancer exhibits a more adverse clinicopathological profile. Younger patients showed longer overall and disease-free survival in this cohort, although these findings should be interpreted with caution given potential differences in treatment exposure, baseline fitness, comorbidity burden and the substantial temporal heterogeneity of the study period.